P seudarthrosis is the most common reported major complication after surgery for adult spinal deformity (ASD). 1 -7 Despite advances in spinal fi xation, pseudarthrosis rates after ASD surgery remain between 17% and 20%. 7 Recombinant human bone morphogenetic protein-2 (rhBMP-2) was approved for human use by the Food and Drug Administration in 2002 as an iliac crest bone graft (ICBG) substitute for single-level anterior lumbar interbody fusion. Initial clinical data reported rhBMP-2 to be superior to ICBG for anterior lumbar interbody fusion procedures, indicating higher fusion rates and no increase in adverse events. 8 -10 However, rhBMP-2 use has expanded beyond the Food and Drug Administration-approved applications. A review of BMP usage (rhBMP-2 and rhMBP-7) in the United States indicated that the number of surgical procedures using BMP between 2003 and 2007 increased 4.3-fold (from 23,900 to 103,194), of which 85% of the procedures used BMP in an off-label application. 11 As off-label rhBMP-2 use has increased, the reported complications associated with rhBMP-2 have also increased. Several studies indicate that complications associated with rhBMP-2 correspond to the location of use including airway compromise when used in the anterior cervical spine, spinal cord compression and myelopathy when used in the posterior cervical spine, endplate resorption and implant subsidence when used in the interbody space, and heterotopic bone formation with associated radiculopathy when used in posterior and transforaminal lumbar interbody fusion. 12 -20 A call for attention to rhBMP-2 associated complications was recently published via a series of articles by Carragee et al . 21 -25 The authors concluded that further independent research is needed to evaluate the early-and long-term complications associated with rhBMP-2 use, including complications that require reoperation, readmission, infection, neurological defi cit, and death.
Little data exist on rhBMP-2 use in ASD. Luhman et al 26 published the earliest single-center experience using rhBMP-2 for ASD. The authors reported high fusion rates (93%-100% and few complications [3 complications in 70 patients]). Recently, Williams et al 27 reported that use of BMP (rhBMP-2 and rhMBP-7) for adult scoliosis was associated with a higher rate of overall complications; however, when controlling for the effects of patient's age and revision procedure status, use of BMP for patients with adult scoliosis was not signifi cantly associated with increased rates of overall complications.
The recent criticisms surrounding rhBMP-2 and the lack of prospective, multicenter data demonstrate that the complication profi les for rhBMP-2 use are poorly defi ned. The purpose of this study was to (1) compare the acute perioperative complications for patients with ASD treated with or without rhBMP-2 in a prospective, multicenter cohort of consecutive patients with ASD and (2) evaluate the complication profi les of rhBMP-2 when used in different locations of the thoracolumbar spine.
MATERIALS AND METHODS
Study data were obtained from a multicenter, prospective, database of consecutively enrolled patients with ASD. Eleven participating sites located in the United States contributed patients to the data set. Institutional review board approval was obtained at all participating centers prior to enrolling patients into the database. Patient enrollment and data collection is ongoing. Patient inclusion criteria for database entry is age more than 18 years and ASD, defi ned as minimum 1 of the following: degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than 20 ° , sagittal vertical axis greater than 5 cm (SVA; distance from C7 plumb line to the posterior, superior corner of S1), pelvic tilt greater than 25 ° (PT; angle between the vertical and the line through the midpoint of the sacral plate to femoral heads axis 28 ), and/or thoracic kyphosis greater than 60 ° . Database exclusion criteria are spinal deformities due to neuromuscular, post-traumatic, neoplastic, rheumatologic, and/or infectious disorders. In addition to the database inclusion criteria, the following criteria served as inclusion criteria for this study: operative treatment for ASD, spinal arthrodesis of 4 or more levels, and minimum 3 months of postoperative follow-up. Patients were divided into 2 treatment groups: those receiving rhBMP-2 (BMP) or no rhBMP-2 (NOBMP). The BMP group was analyzed on the basis of location of rhBMP-2 use: posterior spine only (PBMP), interbody only (IBMP), and interbody + posterior spine (I + PBMP). The I + PBMP group was evaluated by the approach used for the interbody fusion: anterior interbody (AI + PBMP) or posterior interbody (PI + PBMP). Total rhBMP-2 dose and rhBMP-2 dose/spinal level were noted. RhBMP-2 was dosed according to the discretion of the surgeon. The NOBMP group received a combination of ICBG, local bone, and allograft. The BMP group received a combination of local bone and allograft. No BMP patient received ICBG via a separate facial incision and dedicated ICBG harvest. Complications were categorized into cardiopulmonary, gastrointestinal, implant, infection, neurological, operative, renal, and wound. Infectious complications were classifi ed as superfi cial wound infection (superfi cial to the fascia), deep wound infection (deep to the fascia), pneumonia, and urinary tract infection. Complications were labeled major or minor complications as previously recommended, complications requiring surgery were noted, and duration of complication onset from the time of surgery was recorded ( Table 1 ) .
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STATISTICAL METHODS
Descriptive statistics and univariate analyses were performed using JMP (JMP; version 8; SAS Institute Inc., Cary, NC,Distribution analysis was performed for each variable to determine whether distribution was normal and appropriateness of parametric or nonparametric tests. P values of less than 0.05 were considered signifi cant. The adjusted r 2 statistic was used to assess the overall explanatory ability of the linear models. Multivariate regression models were constructed using Multivariate Adaptive Regression Spline Models (MARS). MARS was performed with R version 2.15.2 (2012-10-26) using package earth (earth: Multivariate Adaptive Regression Spline Models. R package version 3.2-3. http://CRAN.R-project.org/package = earth ).
RESULTS
Demographic and Radiographical
Between 2008 and 2012, 279 of 353 consecutive surgically treated patients with ASD enrolled into the database met inclusion criteria and were evaluated for this study. BMP (n = 172) had similar age, body mass index, smoking history, and history of previous spine surgery as NOBMP (n = 107; Table 2 ). Mean BMP follow-up (31.3 vs . 24.8 mo), Charlson Comorbidity Index (1.9 vs . 1.2), and maximal scoliosis (43.0 ° vs . 37.9 ° ) were greater than NOBMP, respectively ( P < 0.05). I + PBMP (n = 62) was older (63.8 yr) than PBMP (n = 103; 54.6 yr) and NOBMP (n = 107; 56.8 yr; P < 0.05; Table 2 ). PBMP had longer mean follow-up, larger mean thoracic curve than I + PBMP and NOBMP, and smaller mean SVA than I + PBMP ( P < 0.05).
Operative
Mean total rhBMP-2 dose (total dose) for all BMP patients was 31.0 mg (range: 2-96 mg). Mean posterior rhBMP-2 dose per level (PSF dose per level) for all BMP patients was 2.5 mg (range: 0.1-6.0 mg). Mean interbody rhBMP-2 dose per level (IBF dose per level) for all BMP patients was 5.0 mg (range: 0.6-18.0 mg; Table 2 ). Mean total dose was greater for I + PBMP (34.9 mg) than for PBMP (30.3 mg) and IBMP (8.8 mg; P < 0.05). Mean PSF dose per level was greater for PBMP (2.6 mg) than for I + PBMP (2.2 mg; P < 0.05; Table 2 ).
Total posterior spinal levels fused, estimated surgical blood loss (EBL), duration of stay in surgical intensive care unit, and hospital stay were similar for BMP versus NOBMP ( Table 2 ) . Mean operative time, number of spinal osteotomies per patient, and number of patients receiving combined anterior and posterior spinal fusion were greater for BMP versus NOBMP. Mean total posterior spinal levels fused were similar for PBMP (12. 3), I + PBMP (11.9), NOBMP (12.0), and for IBMP (9.0; Table 2 ). I + PBMP had more mean interbody fusion levels (2.6) than PBMP (1.6) and NOBMP (1.0; P < 0.05). I + PBMP had greater mean EBL (2.8 L) than PBMP (1.5 L) and NOBMP (1.8 L; P < 0.05), and I + PBMP had greater mean operative time (514.4 min) than NOBMP (414.6 min; P < 0.05). Subanalysis of type of interbody fusion performed within the BMP group, including anterior lumber interbody fusion (n = 18), transforaminal interbody fusion/posterior lumbar interbody fusion (n = 34), and lateral transpsoas (lateral lumbar interbody fusion, n = 7), demonstrated that the subgroup sample sizes were not suffi ciently large enough to draw meaningful statistical conclusions.
Complications
There were 304 complications in the 279 patients who met inclusion criteria for this study ( Table 3 ) . BMP had more total complications per patient (1.4 vs . 0.6), and more minor complications per patient (0.9 vs . 0.2) than NOBMP, respectively ( P < 0.05). NOBMP had more complications requiring surgery per patient than BMP (0.3 vs . 0.2; P < 0.05). Major, wound, infectious, neurological, and renal complications were similar for BMP versus NOBMP. Complications occurring at 3 months or less after surgery per patient were greater BMP versus NOBMP (0.6 vs . 0.2; P < 0.05). Timing of all other specifi c complications was similar for BMP versus NOBMP ( Table 3 ) . PBMP and I + PBMP had more total complications per patient than NOBMP (1.4 vs . 1.4 vs . 0.6, respectively; P < 0.05; Table 3 ). PBMP had more minor complications per patient than I + PBMP and NOBMP (1.0 vs . 0.7 vs . 0.2, respectively; P < 0.05). Major, implant, infectious, neurological, and wound complications per patient were similar for PBMP, I + PBMP, and NOBMP ( Table 3 ) . PBMP had more total complications per patient at 3 months or less than NOBMP (0.7 vs . 0.2; P < 0.05). AI + PBMP and PI + PBMP had similar major, wound, neurological, infectious, and implant complications, requiring surgery per patient as PBMP and NOBMP.
Linear regression analysis of total dose demonstrated signifi cant correlations with total complications as well as major, operative, and infectious complications ( P < 0.05); however, r 2 values indicated little to no demonstrable correlation, as per r 2 interpretation guidelines ( r 2 < 0.09; Table 4 ). 30 Linear regression analysis of total PSF dose and total IBF dose demonstrated that total PSF dose signifi cantly correlated with total, minor, major, neurological, operative, infectious, and deep wound complications ( P < 0.05); however, r 2 values demonstrated little to no correlation ( r 2 < 0.09). Linear regression analysis of PSF dose per level and IBF dose per level demonstrated that PSF dose per level signifi cantly correlated with total complications ( P < 0.05); however, r 2 values demonstrated little to no correlation ( r 2 < 0.09). Multivariate regression modeling (MARS) for specifi c complications using independent variables, including total PSF dose, total IBF dose, and other independent variables, demonstrated that SVA, total PSF dose, body mass index (BMI), EBL, and anterior spinal fusion levels (ASF) levels (in rank order using estimated variable importance methods) best modeled major complications; r 2 values demonstrated moderate correlation ( r 2 = 0.2; Table 5 ). MARS analysis of deep infections demonstrated that SVA, BMI, and total PSF dose were the independent variables that generated the best-fi t model; r 2 value showed moderate correlation ( r MARS analysis for specifi c complications using independent variables including PSF dose per level, IBF dose per level, and other independent variables demonstrated SVA, and total ASF levels best modeled major complications; r 2 value demonstrated moderate correlation ( r 2 = 0.13; 
DISCUSSION
RhBMP-2 has demonstrated effi cacy in promoting higher and/ or accelerated fusion rates for a number of applications.
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As a consequence, the Food and Drug Administration has approved the use of rhBMP-2 for well-defi ned medical conditions. 11 However, the use of rhBMP-2 has extended beyond the approved indications, and, accordingly, so have the reported complication rates. Clear use guidelines and accurate complication profi les for rhBMP-2 must be established to promote responsible use and maximize benefi ts. To achieve these goals, researchers must investigate the complications associated with rhBMP-2 use with the same vigor that the effi cacy for rhBMP-2 to promote fusion is evaluated. The purpose of this study was to evaluate the acute perioperative complication rates associated with rhBMP-2 use in a prospective, consecutive cohort of patients with ASD treated with rhBMP-2 compared with patients with ASD who did not receive rhBMP-2 and to evaluate the impact that location of rhBMP-2 use had upon perioperative complications. Our fi ndings indicate that, at the reported rhBMP-2 doses, there were no consistent associations between use of rhBMP-2 and major, wound, or neurological complications; superfi cial or deep infections; and complications requiring surgery. When associations between rhBMP-2 use and specifi c complications reached statistical signifi cance, linear regression and multivariate modeling demonstrated that the correlation coeffi cient values had small to nonexistent correlations.
Little data exist regarding complications associated with rhBMP-2 use in ASD. Williams et al 27 used the Scoliosis Research Society Morbidity and Mortality registry to compare complications between spinal fusion procedures performed with and without BMP (rhBMP-2 and BMP-7). Excluding anterior cervical fusion procedures, complications were similar between procedures performed with and without BMP. Despite the large study population, limitations to the study include retrospective analysis of a data set that is dependent upon volunteer data submission, with no method to ensure data accuracy or consecutive patient enrollment. Luhman et al 26 published the initial, single-center experience using rhBMP-2 for ASD. At mean follow-up of approximately 17 months, the reported fusion rates ranged from 93% to 100%. There were 3 complications noted; superfi cial wound dehiscence (n = 1), deep wound hematoma (n = 1), and deep wound infection (n = 1). Subsequently, Mulconrey et al , 39 published a longer follow-up on the same patient cohort. Reported fusion rates were again high, including 91% for anterior spinal fusion, 97% for posterior spinal fusion, and 100% for the high-dose posterior spinal fusion. One case of subfascial hematoma was reported. No other wound, infectious, or neurological complications were noted. Maeda et al 40 performed a comparative retrospective analysis of prospectively collected data on 55 consecutive patients with ASD who received multilevel fusion using either ICBG (n = 32) or rhBMP-2 without ICBG (n = 23). Pseudarthrosis rates were higher in the ICBG group (9 of 32 patients; 28.1%) than in the BMP group (1 of 23 patients; 4.3%). One perioperative complication was reported in the BMP group (renal complication; acute tubular necrosis attributed to antifi brinolytic use). No infections or neurological complications were reported. In this study, BMP patients had greater total complication rates and greater minor complication rates than NOBMP but similar wound, neurological, superfi cial, and deep infection complication rates as NOBMP. Reasons for greater total and minor complications in the BMP group are likely multiple. It is possible that an untoward side effect of rhBMP-2 could have played a role in generating greater total and minor complications in the BMP group. However, BMP also had greater Charlson Comorbidity Index, greater operative time, and greater rates of anterior and posterior spinal fusion, all of which are risk factors for perioperative complications. 41 -44 These risk factors may have also accounted for the greater gastrointestinal, cardiopulmonary, and complications occurring less than 3 months per patient in the BMP group. It is also possible that discrepancies in complication reporting at the participating study sites may have accounted for the differences in complication rates between the groups; however, this error was attempted to be mitigated by the prospective, consecutive patient cohort study model with standardized complication reporting and standardized quality analysis of data. 45 NOBMP had more complications that required return to surgery and a greater percentage of complications occurring at the 3-to 12-month postoperative time frame than BMP. This in part is likely due to greater percentage of implant failures occurring at 3 to 12 months in NOBMP compared with BMP. There are several factors that could explain these fi ndings; however, NOBMP had greater pedicle subtraction osteotomies per patient than BMP, and pedicle subtraction osteotomy procedures are a risk factor for rod fracture after ASD surgery. 46 The greatest limitations to this study include (1) lack of long-term follow-up, (2) no analysis of spinal fusion rates, and (3) no reporting of patient health-related quality of life outcomes scores. The mean follow-up for all patients in this study was 28.8 months (range: 3.6-47.9 mo). However, the purpose of this study was to address concerns surrounding previous reports that failed to accurately assess short-term complications associated with rhBMP-2 use; therefore, the inclusion criteria for the analysis were patients with minimum 3 months of follow-up. We recognize the importance of long-term complication analysis for rhBMP-2 and anticipate that as this data set matures, we will report on long-term complications. No attempt was made in this study to evaluate the effi cacy of rhBMP-2 in promoting spinal fusion or improving health-related quality of life outcomes for patients with ASD. The safety, effi cacy, and cost-effectiveness of rhBMP-2 use in ASD must be demonstrated. As this data set matures, we will investigate fusion rates, patient outcomes, and cost-effectiveness of rhBMP-2 for ASD. Finally, the mean rhBMP-2 dose per level reported in this study (PSF dose/level = 2.5 mg, IBF dose/level = 5.0 mg) is below values previously reported for rhBMP-2 use in the spine. 26 , 34 , 36 , 39 , 47 -50 This study is a prospective observational study; consequently, the dosages of rhBMP-2 reported in this study were chosen according to the discretion of the surgeon. The dosages of rhBMP-2 reported may account for our fi ndings, and it is possible that if rhBMP-2 is used in higher doses, greater complication rates may arise.
In conclusion, this prospective, multicenter analysis of consecutive patients with ASD demonstrated that use of rhBMP-2 and the location of rhBMP-2 use, at the reported dosages, did not increase acute major, neurological, or wound complications or superfi cial or deep infections when used in multilevel 
